 |
 |
The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.
Learn more about Cometriq.
No reviews have yet been submitted. Be the first to review this drug.
The investigational multi-tyrosine kinase inhibitor (TKI), lenvatinib (development code: E7080), has today been granted orphan drug designation (ODD) for the...
Researchers have pinpointed a genetic mutation that is strongly associated with an increased risk of death in people with thyroid cancer. The investigators...
Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later...
Looking for answers? Ask a question or go join the Cometriq support group to connect with others who have similar interests.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated Apr 24th, 2013), Cerner Multum™ (updated Apr 19th, 2013), Wolters Kluwer™ (updated Apr 30th, 2013) and others. To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2013 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
